Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:chemical_compound
|
| gptkbp:activities |
serotonin reuptake inhibitor
|
| gptkbp:clinical_trial |
Phase 2
|
| gptkbp:developed_by |
gptkb:Alchem_Laboratories
|
| gptkbp:field_of_study |
pharmacology
|
| https://www.w3.org/2000/01/rdf-schema#label |
ALX-0734
|
| gptkbp:ingredients |
C20 H24 N2 O2
|
| gptkbp:invention |
gptkb:Alchem_Laboratories
|
| gptkbp:is_tested_for |
clinical trials
|
| gptkbp:is_used_for |
treatment of neurological disorders
|
| gptkbp:manager |
oral
|
| gptkbp:side_effect |
dizziness
fatigue nausea |
| gptkbp:status |
investigational drug
|
| gptkbp:targets |
serotonin receptors
|
| gptkbp:type_of |
123456-78-9
|
| gptkbp:weight |
324.42 g/mol
|
| gptkbp:year_created |
gptkb:2020
|
| gptkbp:bfsParent |
gptkb:Ablynx
|
| gptkbp:bfsLayer |
4
|